Differentiating PDTs from Wellness Apps and Evaluating Efficacy

Diana Brixner, PhD, and Ashley Peterson, MHA, explore the distinctions between prescription digital therapeutics (PDTs) and wellness mobile apps, addressing the role of insurance coverage and the clinical validation requirements that payers consider when determining whether to cover PDTs as a treatment modality.

Now Viewing

EP: 1.Differentiating PDTs from Wellness Apps and Evaluating Efficacy

EP: 2.Payer Needs and Strategies for Evaluating and Covering PDTs

EP: 3.Payers Review Process and Effective Strategies for PDT Coverage

EP: 4.Stakeholder Involvement and Evidence Requirements for PDT Coverage Decisions

EP: 5.Dawn of the Age of Adopting PDTs

EP: 6.Identifying the Most Impactful Disease Areas and Patient Populations for PDTs

EP: 7.Evolving Commercialization and Distribution Models for PDTs

EP: 8.Promoting Appropriate PDT Prescribing Through Provider Education and Support

EP: 9.Optimizing Provider Education, Utilization Monitoring, and Value-Based Contracts for PDTs

EP: 10.Optimizing Benefit Design and Implementation for Improved PDT Access

EP: 11.PDTs' Role in Addressing Health Care Disparities and Priorities for Improving PDT Access

Related Videos

Related Content

Advertisement

July 24th 2025

High Burdens of Drug Resistance Found in Children With HIV

Julia Bonavitacola

Mother-to-child transmission often led to pretreatment drug resistance and acquired drug resistance in children living with HIV.

July 24th 2025

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

Brooke McCormick Stephen Lott, PharmD, MS Jonathan Gabison, MD, DABOM

This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.

July 23rd 2025

Immune Cell Phenotypes Linked With Hypothyroidism, IPF

Jared Kaltwasser

Thirty-six immune cell phenotypes were flagged as having an association with idiopathic pulmonary fibrosis (IPF).

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

July 23rd 2025

Real-World Study Finds Brentuximab Vedotin With Chemo Is Safe, Effective in First-line Treatment of PTCL

Mary Caffrey

Brentuximab vedotin combined with cyclophosphamide, doxorubicin, and prednisone (CHP) shows promising results as a first-line treatment in newly diagnosed peripheral T-cell lymphoma (PTCL).

July 23rd 2025

In Data Race, Flatiron Health Touts Tripling of Global Oncology Research Network

Mary Caffrey

Flatiron Health expands its international oncology research network, enhancing real-world data use to improve patient outcomes and cancer care globally.

Related Content

Advertisement

July 24th 2025

High Burdens of Drug Resistance Found in Children With HIV

Julia Bonavitacola

Mother-to-child transmission often led to pretreatment drug resistance and acquired drug resistance in children living with HIV.

July 24th 2025

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

Brooke McCormick Stephen Lott, PharmD, MS Jonathan Gabison, MD, DABOM

This Managed Care Cast episode explores how high costs and inconsistent insurance coverage for incretin mimetics impact obesity management and patient care.

July 23rd 2025

Immune Cell Phenotypes Linked With Hypothyroidism, IPF

Jared Kaltwasser

Thirty-six immune cell phenotypes were flagged as having an association with idiopathic pulmonary fibrosis (IPF).

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

July 23rd 2025

Real-World Study Finds Brentuximab Vedotin With Chemo Is Safe, Effective in First-line Treatment of PTCL

Mary Caffrey

Brentuximab vedotin combined with cyclophosphamide, doxorubicin, and prednisone (CHP) shows promising results as a first-line treatment in newly diagnosed peripheral T-cell lymphoma (PTCL).

July 23rd 2025

In Data Race, Flatiron Health Touts Tripling of Global Oncology Research Network

Mary Caffrey

Flatiron Health expands its international oncology research network, enhancing real-world data use to improve patient outcomes and cancer care globally.